Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie - Seeking Alpha
About 67% of Cerevel Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Cerevel Therapeutics Holdings suggests that many traders are alarmed regarding Cerevel Therapeutics' prospects. The current market sentiment, together with Cerevel Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Cerevel Therapeutics stock news signals to limit their universe of possible portfolio assets.
Cerevel |
Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie Seeking Alpha
Read at news.google.com
Cerevel Therapeutics Fundamental Analysis
We analyze Cerevel Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cerevel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cerevel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Cerevel Therapeutics is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Cerevel Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cerevel Therapeutics stock to make a market-neutral strategy. Peer analysis of Cerevel Therapeutics could also be used in its relative valuation, which is a method of valuing Cerevel Therapeutics by comparing valuation metrics with similar companies.
Peers
Cerevel Therapeutics Related Equities
IGMS | IGM Biosciences | 7.47 | ||||
MLYS | Mineralys Therapeutics, | 5.64 | ||||
DSGN | Design Therapeutics | 4.67 | ||||
APLS | Apellis Pharmaceuticals | 4.39 | ||||
TVTX | Travere Therapeutics | 4.04 | ||||
GPCR | Structure Therapeutics | 2.38 | ||||
BPMC | Blueprint Medicines | 1.29 | ||||
SWTX | SpringWorks Therapeutics | 0.94 | ||||
STOK | Stoke Therapeutics | 0.33 | ||||
DAWN | Day One | 0.65 | ||||
IKNA | Ikena Oncology | 1.16 | ||||
GLUE | Monte Rosa | 1.35 | ||||
TERN | Terns Pharmaceuticals | 1.44 | ||||
HOWL | Werewolf Therapeutics | 2.00 | ||||
CGEM | Cullinan Oncology | 2.08 | ||||
NUVL | Nuvalent | 2.49 | ||||
RNA | Avidity Biosciences | 4.02 | ||||
VTYX | Ventyx Biosciences | 5.97 | ||||
RVMD | Revolution Medicines | 10.46 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Cerevel Stock
If you are still planning to invest in Cerevel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cerevel Therapeutics' history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |